The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women

The present study aims to optimize the treatment in menopause by replacing pharmaceutical preparations containing estroprogestatives with products containing phytoestrogens, with less contraindications and side effects. The objective of the study was to compare the in vivo effects of hormone therapy administered in small doses, with that of soy phytoestrogens, in the evolution of urogenital symptoms in postmenopausal women. The study represents a clinical-statistical research, conducted on 326 patients clinically diagnosed in post menopause with urogenital symptoms that have not been previously treated with hormone replacement therapy (HRT) or phytoestrogens. The patients were divided into three groups of which two with therapy: the first group received treatment in doses of 1 mg estradiol and 0.5 mg norethisterone acetate (NETA) p.o. daily (group of HRT); the second group received an extract standardized at 40% containing 20 mg pure isoflavones (Genistein, Daidzein and Gliciteina) 40 mg p.o. daily (group of phytoestrogens) and a control group without therapy.